The Human IL-23 ELISA Kit is specifically designed for the precise measurement of interleukin-23 (IL-23) levels in human samples, including serum, plasma, and cell culture supernatants. This kit offers unparalleled sensitivity and specificity, ensuring accurate and consistent results for various research applications. IL-23 is a key cytokine involved in immune responses and inflammatory processes, playing a critical role in autoimmune diseases and chronic inflammation.
Monitoring IL-23 levels can provide valuable insights into the pathogenesis of these conditions and facilitate the development of targeted therapies. With its reliable performance and ease of use, the Human IL-23 ELISA Kit is an invaluable tool for researchers studying inflammatory disorders, autoimmune diseases, and the immune system's role in health and disease. Trust in this kit to deliver precise and reliable data for your research needs.
Product Name:
Human IL-23 ELISA Kit
SKU:
HUFI02587
Reactivity:
Human
Assay Type:
Sandwich ELISA, Double Antibody
Sensitivity:
23.438 pg/mL
Range:
39.063-2500 pg/mL
Sample Type:
Serum, Plasma, Cell Culture Supernatant, Cell or Tissue Lysate, Other Liquid Samples
Storage:
2-8°C for 12 months.
Linearity:
Sample
1
2
3
Serum (n = 5)
89-105%
86-99%
82-90%
EDTA Plasma (n = 5)
87-96%
84-100%
87-104%
Heparin Plasma (n = 5)
90-101%
82-100%
87-99%
Recovery:
Sample
1
2
Serum (n = 5)
84-104
93
EDTA Plasma (n = 5)
86-105
93
Heparin Plasma (n = 5)
87-101
95
Note:The below protocol is a sample protocol. Protocols are specific to each batch/lot. For the correct instructions please follow the protocol included in your kit.
Step
Procedure
1
Reagent & Plate Preparation: Equilibrate reagents and TMB substrate to room temperature. Set standard, test sample and control (zero) wells on the pre-coated plate and record their positions.
2
Primary Incubation: Prepare standards, samples, blanks and load into designated wells. Incubate plate at 37°C for 90 minutes to allow antigen binding.
3
Detection Antibody Binding: Add biotin-labeled detection antibody and incubate at 37°C for 60 minutes.
4
HRP-Streptavidin Binding: Add HRP-Streptavidin (SABC) and incubate at 37°C for 30 minutes.
5
Color Development: Add TMB substrate and incubate in the dark for 10–20 minutes.
6
Stop Reaction & Reading: Add stop solution and measure absorbance at 450 nm immediately.
Sample Type
Protocol
Serum
Allow blood to clot, centrifuge at 1000 × g for 20 minutes, collect supernatant supernatant and store appropriately.
Plasma
Collect using anticoagulant tubes, centrifuge at 1000 × g for 15 minutes at 2–8°C and collect plasma.
Tissue Homogenate
Homogenize tissue in PBS with protease inhibitors, centrifuge and collect supernatant.
Cell Culture Supernatant
Centrifuge at 2500 rpm for 5 minutes and collect clarified supernatant.
Cell Lysate
Lyse cells using lysis buffer with protease inhibitors, centrifuge and collect protein supernatant.
Other Sample Types
For more information about how to process other sample types, (e.g., body fluids, breast milk & more), please contact our Tech Support Team at techsupport@assaygenie.com.
Component
Quantity
Storage
48T
96T
ELISA Microplate (Dismountable)
8×6
8×12
Place the test strips into a sealed foil bag with the desiccant. Store for 1 month at 2-8°C; Store for 12 months at -20°C.
Lyophilized Standard
1 vial
2 vial
Place the standards into a sealed foil bag with the desiccant. Store for 1 month at 2-8°C; Store for 12 months at -20°C.
Biotin-labeled Antibody (Concentrated, 100X)
60 ul
120 ul
2-8°C (Avoid direct light)
HRP-Streptavidin Conjugate (SABC, 100X)
60 ul
120 ul
2-8°C (Avoid direct light)
TMB Substrate
5 ml
10 ml
2-8°C (Avoid direct light)
Sample Dilution Buffer
10 ml
20 ml
2-8°C
Antibody Dilution Buffer
5 ml
10 ml
2-8°C
SABC Dilution Buffer
5 ml
10 ml
2-8°C
Stop Solution
5 ml
10 ml
2-8°C
Wash Buffer(25X)
15 ml
30 ml
2-8°C
Plate Sealer
3 pieces
5 pieces
-
Technical Manual
1 copy
1 copy
-
Neasa Mc Gettigan et al.
Impact of a physician-led exercise programme on quality of life, muscle mass and clinical response in inflammatory bowel disease patients during induction with disease-modifying therapy: a study protocol
